Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3032 Target Snapshot

Serine/threonine-protein kinase N2 · SINGLE PROTEIN · Homo sapiens

1,614Compounds
326Assays
11Approved Drugs
1,202.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q16513. Use UniProt Q16513 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q16513 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase N2 as ChEMBL target CHEMBL3032, mapped to UniProt Q16513. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase N2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3032
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16513
Serine/threonine-protein kinase N2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase N2 is the right protein anchor across sources, using UniProt Q16513 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase N2
UniProt AccessionQ16513
Component TypeProtein
Sequence Length984 aa

Serine/threonine-protein kinase N2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase N2, mapped to UniProt Q16513. Sequence length is 984 aa.

Mapped IDQ16513
Review nameSerine/threonine-protein kinase N2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

11
Approved
8
Phase III
13
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50103.0
KI733.0
KD366.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1980995 9.1 Ki 0.7943 Preclinical
CHEMBL603469 8.74 Kd 1.8 Clinical
CHEMBL388978 8.71 IC50 1.97 Preclinical
CHEMBL1969588 8.6 Ki 2.512 Preclinical
CHEMBL1968930 8.6 Ki 2.512 Preclinical
CHEMBL1998432 8.6 Ki 2.512 Preclinical
CHEMBL388978 8.6 Kd 2.5 Preclinical
CHEMBL4576489 8.4 Kd 4.0 Preclinical
CHEMBL1970903 8.3 Ki 5.012 Preclinical
CHEMBL225519 8.3 Ki 5.012 Preclinical
Distribution

pChEMBL Value Distribution

78
5.0
91
5.5
90
6.0
58
6.5
46
7.0
35
7.5
20
8.0
9
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
BARICITINIB
CHEMBL2105759
Approved 2017
Assay Landscape

Assay Landscape

326
Total Assays
283
Tested Compounds
2
Assay Types
Binding — 325 assays, 106 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 269 83 6.3
cell-based format 24 8 6.2
assay format 17 0
subcellular format 15 15 6.5
Functional — 1 assays, 283 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 283 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine